Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and ...

Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared ...

Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, ...

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today reported financial results for the second quarter ended June 30, 2025. “We continued to execute on our new strategy of ...

Welcome to the H.C. Wainwright 27th Annual Global Investment Conference. I'm Dr. Katherine Degen, an associate biotech research analyst at the firm. I'd like to take a moment to welcome Erik Holmlin ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president ...

Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.

Operator: Good day and thank you for standing by. Welcome to the Bionano Q2 Financial Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there ...

Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.

Bionano Genomics remains under watch as market volatility raises attention on clinical adoption, funding discipline, and diagnostics demand.